We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CryerHealth Establishes Personalized Medicine Practice to Support Companies Committed to Genomic-Based Innovation

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "CryerHealth Establishes Personalized Medicine Practice to Support Companies Committed to Genomic-Based Innovation"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CryerHealth, LLC, has announced that it has launched a Personalized Medicine Practice. The new practice will focus on designing commercialization and external affairs strategies for companies developing and marketing genomic-based diagnostics and therapies.

"The ultimate patient-centric solutions can be found through personalized medicine," said Dennis R. Cryer, MD, FAHA, Chief Medical Officer. "Working with clients to support the provision of individualized risk-assessment, therapy selection, and intervention targeting is a logical extension of the CryerHealth approach to healthcare transformation."

Raith Erickson, RPh, MBA, who most recently led managed care, business development, and government affairs at deCODE genetics, leads the CryerHealth Personalized Medicine Practice. According to Erickson, the practice offers a wide range of services to help clients define and meet their business objectives. Primary among them are clinical trial design and recruitment optimization, medical external affairs, payor strategies, and patient/physician education.

"It is exciting to join the CryerHealth team of professionals to be able to leverage our collective experience with genetics, biomarkers, rare diseases, transplantation, and oncology on behalf of clients to create and expand their market share, attain reimbursement, and develop strong relationships with stakeholders so that genomic-based therapies are adopted and accessible to patients," said Erickson. "The promise and potential of personalized medicine is to make healthcare more cost- and clinically-effective, which benefits everyone."

Erickson brings 18 years of healthcare experience to the new practice. He has provided leadership and innovation in the pharmacy, payor, and genetic diagnostics spaces. In addition to his work for the global leader in human genetics diagnostics, Erickson worked as a pharmacy benefit expert at CIGNA and brought FluMist to market as part of the marketing team at MedImmune. Erickson received a Bachelor of Science degree in Pharmacy and Master in Business Administration from Drake University.